266 related articles for article (PubMed ID: 1469924)
1. 3-(Phenylamino)alanine, a novel aniline-derived amino acid associated with the eosinophilia-myalgia syndrome: a link to the toxic oil syndrome?
Mayeno AN; Belongia EA; Lin F; Lundy SK; Gleich GJ
Mayo Clin Proc; 1992 Dec; 67(12):1134-9. PubMed ID: 1469924
[TBL] [Abstract][Full Text] [Related]
2. Biotransformation of 3-(phenylamino)-1,2-propanediol to 3-(phenylamino)alanine: a chemical link between toxic oil syndrome and eosinophilia-myalgia syndrome.
Mayeno AN; Benson LM; Naylor S; Colberg-Beers M; Puchalski JT; Gleich GJ
Chem Res Toxicol; 1995; 8(7):911-6. PubMed ID: 8555405
[TBL] [Abstract][Full Text] [Related]
3. 3-(Phenylamino)alanine--a link between eosinophilia-myalgia syndrome and toxic oil syndrome?
Philen RM; Hill RH
Mayo Clin Proc; 1993 Feb; 68(2):197-200. PubMed ID: 8423703
[No Abstract] [Full Text] [Related]
4. Generation of quinoneimine intermediates in the bioactivation of 3-(N-phenylamino)alanine (PAA) by human liver microsomes: a potential link between eosinophilia-myalgia syndrome and toxic oil syndrome.
Martínez-Cabot A; Messeguer A
Chem Res Toxicol; 2007 Oct; 20(10):1556-62. PubMed ID: 17892268
[TBL] [Abstract][Full Text] [Related]
5. Rapid HPLC screening method for contaminants found in implicated L-tryptophan associated with eosinophilia myalgia syndrome and adulterated rapeseed oil associated with toxic oil syndrome.
Williamson BL; Tomlinson AJ; Hurth KM; Posada de la Paz M; Gleich GJ; Naylor S
Biomed Chromatogr; 1998; 12(5):255-61. PubMed ID: 9787895
[TBL] [Abstract][Full Text] [Related]
6. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia.
Kaufman LD; Krupp LB
Curr Opin Rheumatol; 1995 Nov; 7(6):560-7. PubMed ID: 8579979
[TBL] [Abstract][Full Text] [Related]
7. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia.
Silver RM
Curr Opin Rheumatol; 1993 Nov; 5(6):802-8. PubMed ID: 8117543
[TBL] [Abstract][Full Text] [Related]
8. Tryptophan contaminants associated with eosinophilia-myalgia syndrome. The Eosinophilia-Myalgia Studies of Oregon, New York and New Mexico.
Philen RM; Hill RH; Flanders WD; Caudill SP; Needham L; Sewell L; Sampson EJ; Falk H; Kilbourne EM
Am J Epidemiol; 1993 Aug; 138(3):154-9. PubMed ID: 8356958
[TBL] [Abstract][Full Text] [Related]
9. The eosinophilia-myalgia syndrome and the toxic oil syndrome. Pursuing parallels.
Hertzman PA
Adv Exp Med Biol; 1996; 398():339-42. PubMed ID: 8906286
[No Abstract] [Full Text] [Related]
10. Synthesis and analysis of contaminants in ems-related tryptophan.
Steinhart H; van Wickern B; Meyer K; Simat T
Adv Exp Med Biol; 1996; 398():667-75. PubMed ID: 8906342
[No Abstract] [Full Text] [Related]
11. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia.
Silver RM
Curr Opin Rheumatol; 1992 Dec; 4(6):851-6. PubMed ID: 1457280
[TBL] [Abstract][Full Text] [Related]
12. Study of apoptosis in human lymphocytes by toxic substances implicated in toxic oil syndrome.
Gallardo S; Cárdaba B; del Pozo V; de Andrés B; Cortegano I; Jurado A; Tramón P; Palomino P; Lahoz C
Toxicology; 1997 Mar; 118(1):71-82. PubMed ID: 9074655
[TBL] [Abstract][Full Text] [Related]
13. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia.
Bolster MB; Silver RM
Curr Opin Rheumatol; 1994 Nov; 6(6):642-9. PubMed ID: 7865387
[TBL] [Abstract][Full Text] [Related]
14. [Eosinophilia myalgia syndrome (EMS) caused by L-tryptophan product and toxic oil syndrome (TOS) caused by denatured rape-seed oil].
Maitani T; Saitoh H
Shokuhin Eiseigaku Zasshi; 2009 Dec; 50(6):279-91. PubMed ID: 20065617
[No Abstract] [Full Text] [Related]
15. Toxic oil syndrome and eosinophilia-myalgia syndrome: May 8-10, 1991, World Health Organization meeting report.
Philen RM; Posada M
Semin Arthritis Rheum; 1993 Oct; 23(2):104-24. PubMed ID: 8266108
[TBL] [Abstract][Full Text] [Related]
16. Toxic oil syndrome: a current clinical and epidemiologic summary, including comparisons with the eosinophilia-myalgia syndrome.
Kilbourne EM; Posada de la Paz M; Abaitua Borda I; Diez Ruiz-Navarro M; Philen RM; Falk H
J Am Coll Cardiol; 1991 Sep; 18(3):711-7. PubMed ID: 1869734
[TBL] [Abstract][Full Text] [Related]
17. Peak AAA fatty acid homolog contaminants present in the dietary supplement l-Tryptophan associated with the onset of eosinophilia-myalgia syndrome.
Klarskov K; Gagnon H; Racine M; Boudreault PL; Normandin C; Marsault E; Gleich GJ; Naylor S
Toxicol Lett; 2018 Sep; 294():193-204. PubMed ID: 29800716
[TBL] [Abstract][Full Text] [Related]
18. Identification of four metabolites of 3-(phenylamino)alanine, a constituent in L-tryptophan products implicated in eosinophilia-myalgia syndrome, in rats.
Adachi J; Mio T; Ueno Y; Naito T; Nishimura A; Fujiwara S; Sumino K; Tatsuno Y
Arch Toxicol; 1994; 68(8):500-5. PubMed ID: 7802590
[TBL] [Abstract][Full Text] [Related]
19. Subchronic toxicity of 3-phenylamino alanine, an impurity in L-tryptophan reported to be associated with eosinophilia-myalgia syndrome.
Sato F; Hagiwara Y; Kawase Y
Arch Toxicol; 1995; 69(7):444-9. PubMed ID: 8526739
[TBL] [Abstract][Full Text] [Related]
20. Alterations in tryptophan metabolism in the toxic oil syndrome and in the eosinophilia-myalgia syndrome.
Silver RM; Sutherland SE; Carreira P; Heyes MP
J Rheumatol; 1992 Jan; 19(1):69-73. PubMed ID: 1532618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
